Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Gsk (GLAXF) Payables (2016 - 2025)

Historic Payables for Gsk (GLAXF) over the last 17 years, with Q3 2025 value amounting to -$25.0 billion.

  • Gsk's Payables fell 3233.73% to -$25.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.0 billion, marking a year-over-year decrease of 3233.73%. This contributed to the annual value of -$22.6 billion for FY2024, which is 19741.02% down from last year.
  • Latest data reveals that Gsk reported Payables of -$25.0 billion as of Q3 2025, which was down 3233.73% from -$20.1 billion recorded in Q2 2025.
  • Over the past 5 years, Gsk's Payables peaked at $28.5 billion during Q4 2021, and registered a low of -$27.0 billion during Q2 2021.
  • For the 5-year period, Gsk's Payables averaged around -$12.7 billion, with its median value being -$19.3 billion (2022).
  • As far as peak fluctuations go, Gsk's Payables skyrocketed by 7854.86% in 2022, and later plummeted by 28945.32% in 2023.
  • Gsk's Payables (Quarter) stood at $28.5 billion in 2021, then fell by 16.85% to $23.7 billion in 2022, then decreased by 2.34% to $23.2 billion in 2023, then crashed by 198.02% to -$22.7 billion in 2024, then decreased by 10.14% to -$25.0 billion in 2025.
  • Its Payables stands at -$25.0 billion for Q3 2025, versus -$20.1 billion for Q2 2025 and -$21.5 billion for Q1 2025.